Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Shilpa Medicare Limited is a leading Indian pharmaceutical company specializing in the development and manufacturing of specialty and generic drugs, particularly in oncology and other complex therapies. The company has a strong foothold in both domestic and international markets, with a significant presence in the US and Europe, driven by its robust pipeline of ANDAs and a focus on high-value, niche segments.
Shilpa Medicare generates revenue primarily through the sale of generic and specialty drugs, leveraging its strong R&D capabilities to develop complex formulations. The company benefits from pricing power in its specialty segment due to limited competition and high barriers to entry, particularly in oncology. Additionally, its contract manufacturing services provide a steady revenue stream.
Approval of ANDAs by the FDA, particularly for oncology drugs
Expansion of manufacturing capabilities and facilities in India and the US
Strategic partnerships or collaborations with global pharmaceutical companies
Market share growth in the US generic drug market
Regulatory changes impacting drug approvals and pricing
Technological disruption in drug development processes
Increasing competition from generic drug manufacturers in emerging markets
Potential entry of large multinational companies into niche markets
Potential liquidity issues due to negative free cash flow ($-0.8B)
High capital expenditures ($3.7B) could strain financial resources if not managed effectively
moderate - The demand for pharmaceuticals is generally stable, but economic downturns can affect healthcare spending and insurance coverage.
Low - Shilpa's low debt levels (Debt/Equity of 0.25) minimize the impact of rising interest rates on financing costs, although higher rates could affect overall market valuations.
minimal - The company has a strong balance sheet with manageable debt levels, reducing reliance on credit markets.
growth - Investors are likely drawn to Shilpa's strong revenue growth and expanding market presence in specialty pharmaceuticals.
moderate - The stock has shown significant returns (79.1% over 6 months), indicating some volatility, but its fundamentals provide a degree of stability.
